DOCSLIB.ORG

View the 2019 Index

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Index A Abnormal uterine bleeding (AUB), heart failure, 311 Achondroplasia, 454 A-a gradient 618, 619 hypertension, 319 chromosome disorder, 64 in elderly, 654 adenomyosis, 634 naming convention for, 253 endochondral ossification in, 450 with hypoxemia, 654, 655 anemia with, 410 preload/afterload effects, 282 inheritance, 60 restrictive lung disease, 661 Asherman syndrome, 634 teratogenicity, 600 AChR (acetylcholine receptor), 229 Abacavir, 201, 203 leiomyoma (fibroid), 634 Acetaldehyde, 72 Acid-base physiology, 580 Abciximab, 122 polyps (endometrial), 634 Acetaldehyde dehydrogenase, 70, 72 Acidemia, 580 Glycoprotein IIb/IIIa inhibitors, thecoma, 632 Acetaminophen, 474 diuretic effect on, 595 429 ABO blood classification, 397 vs. aspirin for pediatric patients, 474 Acid-fast oocysts, 177 thrombogenesis and, 403 newborn hemolysis, 397 free radical injury and, 210 Acid-fast organisms, 125, 140, 155 Abdominal aorta, 357 Abruptio placentae, 626 hepatic necrosis from, 249 Acidic amino acids, 81 atherosclerosis in, 305, 687 cocaine use, 600 N-acetylcysteine for overdose, 671 Acid maltase, 86 bifurcation of, 649 preeclampsia, 629 for osteoarthritis, 458 Acidosis, 578, 580 Abdominal aortic aneurysm, 306 Abscess, 470 toxicity effects, 474 contractility in, 282 Abdominal colic acute inflammation and, 215 toxicity treatment for, 247 hyperkalemia with, 578 lead poisoning, 411 lung, 670 Acetazolamide, 252, 539, 594 Acid phosphatase in neutrophils, 398 Abdominal pain Absence seizures idiopathic intracranial Acid reflux bacterial peritonitis, 384 characteristics of, 505 hypertension, 509 H2 blockers for, 392 Budd-Chiari syndrome, 386, 676 drug therapy for, 532 metabolic acidosis, 580 proton pump inhibitors for, 392 cilostazol/dipyridamole, 429 treatment, 685 in nephron physiology, 573 Acid suppression therapy, 392 Clostridium difficile, 675 Absolute risk reduction (ARR), 258, pseudotumor cerebri, 509 Acinetobacter baumannii diabetic ketoacidosis and, 346 691 site of action, 593 highly resistant bacteria, 198 ectopic pregnancy, 627 Absorption disorders and anemia, 410 Acetoacetate metabolism, 90 Acinetobacter spp. Henoch-Schönlein purpura, 318, AB toxin, 132 Acetone breath, 346 nosocomial infections, 185 676 Abuse. See also Child abuse Acetylation Acne, 466, 468 hypercalcemia, 579 dependent personality disorder chromatin, 34 danazol, 643 hyperparathyroidism, 342 and, 553 posttranslation, 45 PCOS, 631 intussussception, 379 intimate partner violence, 267 Acetylcholine (ACh) tetracyclines for, 192 irritable bowel syndrome, 376, 377 Acalculia, 499 anticholinesterase effect on, 240 Acquired hydrocele (scrotal), 638 McBurney sign, 676 Acalculous cholecystitis, 390 change with disease, 483 Acrodermatitis enteropathica, 71 Meckel diverticulum, 604 Acamprosate opioid analgesics, 538 Acromegaly, 343 pancreas divisum, 354 alcoholism, 559, 685 pacemaker action potential and, carpal tunnel syndrome, 451 pancreatic cancer, 391 Acanthocytes, 406 295 GH, 327 panic disorder, 551 Acanthocytosis Acetylcholine (ACh) receptor octreotide for, 393 periumbilical, 377 in vitamin E deficiency, 70 agonists, 229, 237, 538 somatostatin analogs for, 325 polyarteritis nodosa, 317 in abetalipoproteinemia, 94 autonomic drugs and, 239 somatostatin for, 350 porphyria, 417 Acantholysis, 466 Acetylcholinesterase Acromion, 438 postprandial, 357 Acanthosis, 466 in amniotic fluid, 479 Actin RLQ pain, 378 psoriasis, 468 Acetylcholinesterase (AChE) cytoskeleton, 48 Rovsing sign, 676 Acanthosis nigricans, 229, 466, 472, malathion, 200 muscular dystrophies, 61 RUQ, 390 631 neural tube defects and, 479 Actin filaments Abdominal striae, 333 stomach cancer, 373 Acetylcholinesterase (AChE) epithelial cells, 465 Abdominal wall Acarbose, 349 inhibitors Acting out, 542 inguinal hernias, 362, 363 Accessory nerve (CN XI), 494 cholinergic drugs and, 239 Actinic keratosis, 472 ventral defects, 352, 354 arm abduction, 438 naming convention for, 253 associations of, 689 Abducens nerve (CN VI), 494 functions of, 494 for neuromuscular junction squamous cell carcinoma, 473 function of, 494 lesion of, 520 disease, 463 Actinomyces israelii location, 492 location, 492 toxicity treatment for, 247 labs/findings, 679 ocular motility, 528 pathway for, 493 Acetyl-CoA carboxylase oral infections, 186 palsy, 529 Accessory pancreatic duct, 354, 362 fatty acid synthesis, 73 pigment production, 128 pathway for, 493 Accountable care organization, 269 vitamin B7 and, 68 Actinomyces spp. Abduction Accuracy vs. precision, 259 Achalasia, 370 anaerobic organism, 127 arm, 438 Acebutolol, 245 esophageal cancer and, 372 Gram-positive algorithm, 134 hand, 438 ACE inhibitors, 596 LES tone in, 365 Nocardia spp. vs., 139 hip, 445 acute coronary syndromes, 310 Achilles reflex, 498 penicillin G/V for, 187 Abductor digiti minimi muscle, 439 C1 esterase inhibitor deficiency, Achilles tendon xanthomas, 304, 674 Action potentials Abductor pollicis brevis muscle, 439 107 Achlorhydria axonal, 482 Abetalipoproteinemia, 94, 406 dilated cardiomyopathy, 311 stomach cancer, 373 motor neurons, 295 Abnormal passive adduction, 443 dry cough, 251 VIPomas, 365 muscle contraction, 448 732 INDEX INDEX Action potentials (continued) Adaptive immune system Adjustment disorder, 552 local anesthetics, 537 myocardial, 294 dendritic cells in, 400 Adnexal (ovarian) torsion, 611 loop diuretics, 594 pacemaker, 295 Adaptive immunity, 99 Adoption studies, 256 opioid analgesics, 538 ventricular, 295 lymphocytes in, 401 ADPKD (Autosomal dominant osteonecrosis of jaw, 475 Action/willpower, 556 Addiction, 556 polycystic kidney disease) ototoxicity, 433, 594 Activated carriers, 75 Addison disease, 334 saccular aneurysms and, 504 proton pump inhibitors, 392 Active errors, 272 metabolic acidosis in, 580 ADP receptor inhibitors, 429 restrictive lung disease, 661 Active immunity, 110 presentation, 676 ADP ribosyltransferases, 132 Reye syndrome as, 475 Acute chest syndrome, 414 Additive drug interactions, 233 adrenal, 616 spironolactone endocrine effects, Acute cholestatic hepatitis Adduction Adrenal adenomas 595 drug reactions and, 248 arm (rotator cuff), 438 Cushing syndrome, 333 tardive dyskinesia, 394 macrolides, 193 hand, 439 hyperaldosteronism, 334 teratogenicity, 428, 432, 475 Acute coronary syndrome hip, 445, 446 Adrenal carcinomas thromboembolic events, 435 ADP receptor inhibitors for, 429 thigh, 444 Cushing syndrome, 333 toxicities and side effects, heparin for, 427 Adductor brevis, 444 Li-Fraumeni syndrome, 225 247–251 treatments for, 310 Adductor longus, 444, 446 P-glycoprotein in, 228 Aedes mosquitoes Acute cystitis, 582 Adductor longus muscle, 362 Adrenal cortex, 322 yellow fever transmission, 168 Acute disseminated (postinfectious) Adductor magnus, 444 embryologic derivatives, 599 Aerobic metabolism encephalomyelitis, 512 Adenine progesterone production, 616 ATP production, 74 Acute dystonia, 557 methylation of, 34 Adrenal enzyme deficiencies fed state, 91 treatment of, 241 Shiga/Shiga-like toxins and, 132 (congenital), 328 vitamin B1 (thiamine), 66 Acute gastritis, 373 Adenocarcinoma Adrenal gland Aerobic organisms Acute hemolytic transfusion lungs, 669 cortical development of, 599 culture requirements, 126 reactions, 114 vaginal, 630 Adrenal hemorrhage, 675 Afferent arteriole, 568 Acute hemorrhagic cystitis, 164 Adenocarcinomas Waterhouse-Friderichsen ANP/BNP effect on, 576 Acute inflammation carcinogens causing, 226 syndrome, 334 constriction of, 571 characteristics of, 215 esophagus, 372 Adrenal hyperplasia dopamine effects, 577 Acute inflammatory demyelinating gastric, 217, 226 Cushing syndrome, 333 filtration, 571 polyradiculopathy, 512 lung, 225 hyperaldosteronism and, 334 Afferent nerves, 299 Acute intermittent porphyria, 417 nomenclature for, 221 Adrenal insufficiency, 334 Aflatoxins, 153 Acute interstitial nephritis, 591 nonbacterial thrombotic adrenoleukodystrophy, 47 as carcinogen, 226 Acute kidney injury, 590 endocarditis and, 229 anovulation with, 631 hepatocellular carcinoma, 386 Acute lymphoblastic leukemia (ALL), pancreas, 362, 391 fludrocortisone for, 350 African sleeping sickness, 156 424 deficiency, 67 pancreatic, 227 vitamin B5 Afterload associations with, 689 paraneoplastic syndromes, 229 Adrenal medulla, 322 auscultation and, 293 methotrexate for, 432 pectinate line, 360 neuroblastomas of, 335 cardiac output, 282 oncogenes and, 225 prostatic, 640 pheochromocytomas in, 336 in shock, 312 Acute mesenteric ischemia, 380 stomach, 373, 688 tumors, 688 Agammaglobulinemia Acute myelogenous leukemia (AML), Adenohypophysis, 323 Adrenal steroids, 328 chromosome affected, 64 424 embryologic derivation, 599 Adrenal zona fasciculata, 329 Agars (bacterial culture), 126 chromosomal translocations, 426 hypothalamus and, 486 Adrenocortical adenomas, 688 Agenesis, 599 cytarabine for, 432 Adenomas Adrenocortical atrophy Müllerian, 608 myelodysplastic syndromes, 423 bone, 456 Addison disease, 334 uterovaginal, 625 Acute myeloid leukemia (AML) colorectal, 383 exogeneous corticosteroids, 333 associations with, 689 nomenclature for, 221 Adrenocortical insufficiency Age-related amyloidosis, 212 Acute pancreatitis, 391 primary hyperparathyroidism, 341 drug reaction and, 248 Age-related macular degeneration, associations, 689 salivary gland, 370 presentation, 676 524 DIC and, 689 thyroid, 340 Adrenocorticotropic hormone Aging changes, 268 hyperparathyroidism, 342 Adenomatous colonic polyps, 381 (ACTH) Agnosia, 499 necrosis and, 209 Adenomyosis (endometrial), 634 adrenal cortex regulation of, 322 Agonist Acute pericarditis, 314 uterine bleeding from,
Recommended publications
  • Developmental Venous Anomaly: MR and Angiographic ­Features

    Developmental Venous Anomaly: MR and Angiographic ­Features

    JBR–BTR, 2014, 97: 17-20. DEVELOPMENTAL VENOUS ANOMALY: MR AND ANGIOGRAPHIC FEATURES M. Faure1, M. Voormolen1, T. Van der Zijden1, P.M. Parizel1 Developmental venous anomaly (DVA) is probably the most common anomaly of the intracranial vasculature. DVAs consist of multiple, radially oriented dilated medullary veins that converge into a transcerebral vein. We describe the imaging findings of this vascular anomaly in different patients and the role of different imaging modalities. Key-words: Cerebral blood vessels, abnormalities – Cerebral blood vessels, MR – Cerebral angiography. Developmental venous anomaly (DVA) was first considered a rare vascular malformation (1, 2). Nowa- days, with the advent of Computed Tomography (CT) and especially Magnetic Resonance Imaging (MRI), DVAs are seen every week to month by radiologists (3, 4). Most DVAs are solitary, asymptomatic lesions and are discovered incidentally. They have a relatively benign nature with a low incidence of hemorrhage. When they do bleed, this is thought to be due to associated vascular mal- formations, like cavernous angiomas. The typical angiographic appearance of a DVA is a caput medusae appear- ance in the venous phase. MRI com- bined with MR angiography (MRA) replaces angiography in most un- A B complicated cases as a non-invasive alternative (3, 5). Case reports Case 1 A 32-year-old woman presented with headache, with no particular location and no neurological deficit. MRI of the brain was made in another hospital that showed a flow void running transcerebral, suggestive for a vascular malformation (Fig. 1A,B). Initially, there was no gadolinium contrast given and an arterial feeder could thus not be excluded with MRI.
  • Pediatrics-EOR-Outline.Pdf

    Pediatrics-EOR-Outline.Pdf

    DERMATOLOGY – 15% Acne Vulgaris Inflammatory skin condition assoc. with papules & pustules involving pilosebaceous units Pathophysiology: • 4 main factors – follicular hyperkeratinization with plugging of sebaceous ducts, increased sebum production, Propionibacterium acnes overgrowth within follicles, & inflammatory response • Hormonal activation of pilosebaceous glands which may cause cyclic flares that coincide with menstruation Clinical Manifestations: • In areas with increased sebaceous glands (face, back, chest, upper arms) • Stage I: Comedones: small, inflammatory bumps from clogged pores - Open comedones (blackheads): incomplete blockage - Closed comedones (whiteheads): complete blockage • Stage II: Inflammatory: papules or pustules surrounded by inflammation • Stage III: Nodular or cystic acne: heals with scarring Differential Diagnosis: • Differentiate from rosacea which has no comedones** • Perioral dermatitis based on perioral and periorbital location • CS-induced acne lacks comedones and pustules are in same stage of development Diagnosis: • Mild: comedones, small amounts of papules &/or pustules • Moderate: comedones, larger amounts of papules &/or pustules • Severe: nodular (>5mm) or cystic Management: • Mild: topical – azelaic acid, salicylic acid, benzoyl peroxide, retinoids, Tretinoin topical (Retin A) or topical antibiotics [Clindamycin or Erythromycin with Benzoyl peroxide] • Moderate: above + oral antibiotics [Minocycline 50mg PO qd or Doxycycline 100 mg PO qd], spironolactone • Severe (refractory nodular acne): oral
  • Repercussions of Inborn Errors of Immunity on Growth☆ Jornal De Pediatria, Vol

    Repercussions of Inborn Errors of Immunity on Growth☆ Jornal De Pediatria, Vol

    Jornal de Pediatria ISSN: 0021-7557 ISSN: 1678-4782 Sociedade Brasileira de Pediatria Goudouris, Ekaterini Simões; Segundo, Gesmar Rodrigues Silva; Poli, Cecilia Repercussions of inborn errors of immunity on growth☆ Jornal de Pediatria, vol. 95, no. 1, Suppl., 2019, pp. S49-S58 Sociedade Brasileira de Pediatria DOI: https://doi.org/10.1016/j.jped.2018.11.006 Available in: https://www.redalyc.org/articulo.oa?id=399759353007 How to cite Complete issue Scientific Information System Redalyc More information about this article Network of Scientific Journals from Latin America and the Caribbean, Spain and Journal's webpage in redalyc.org Portugal Project academic non-profit, developed under the open access initiative J Pediatr (Rio J). 2019;95(S1):S49---S58 www.jped.com.br REVIEW ARTICLE ଝ Repercussions of inborn errors of immunity on growth a,b,∗ c,d e Ekaterini Simões Goudouris , Gesmar Rodrigues Silva Segundo , Cecilia Poli a Universidade Federal do Rio de Janeiro (UFRJ), Faculdade de Medicina, Departamento de Pediatria, Rio de Janeiro, RJ, Brazil b Universidade Federal do Rio de Janeiro (UFRJ), Instituto de Puericultura e Pediatria Martagão Gesteira (IPPMG), Curso de Especializac¸ão em Alergia e Imunologia Clínica, Rio de Janeiro, RJ, Brazil c Universidade Federal de Uberlândia (UFU), Faculdade de Medicina, Departamento de Pediatria, Uberlândia, MG, Brazil d Universidade Federal de Uberlândia (UFU), Hospital das Clínicas, Programa de Residência Médica em Alergia e Imunologia Pediátrica, Uberlândia, MG, Brazil e Universidad del Desarrollo,
  • Cytology of Myeloma Cells

    Cytology of Myeloma Cells

    J Clin Pathol: first published as 10.1136/jcp.29.10.916 on 1 October 1976. Downloaded from J. clin. Path., 1976, 29, 916-922 Cytology of myeloma cells F. G. J. HAYHOE AND ZOFIA NEUMAN1 From the Department of Haematological Medicine, Cambridge University SYNOPSIS A cytological, cytochemical, and cytometric study of plasma cells from 195 cases of multiple myeloma showed that, contrary to earlier reports, flaming cells, thesaurocytes, and intra- nuclear inclusions are not confined to IgA-secreting cases but are common also in IgG and Bence Jones varieties of myeloma. IgA-secreting cells are not larger, nor do they have a lower nuclear- cytoplasmic ratio than other myeloma cells. On average, for a given mass of tumour, Bence-Jones, IgG, and IgA varieties of myeloma produce amounts of paraprotein in the ratio 1 to 1 6 to 2-7. In 1961 Paraskevas et al reported a correlation the results of a larger scale survey carried out some between the morphological features of plasma cells years ago but previously unpublished. in myeloma and the type of immunoglobulin secreted. The cases studied included 12 with y1A Material and methods (f2A, IgA) myeloma, 30 with y (IgG) myeloma, and six myelomas without M protein (probably Bence The study was performed on bone marrow smearscopyright. Jones myelomas). Flaming cells, thesaurocytes, and from 200 consecutive patients newly entered into a intranuclear, PAS-positive inclusion bodies were comparative trial of treatments in myeloma, under found only in cases of IgA myeloma, and flaming the auspices of the Medical Research Council. Five cells especially were present in most cases and in patients were subsequently excluded as not confirmed high percentage in several.
  • Aortic Thrombus Causing a Hypertensive Emergency

    Aortic Thrombus Causing a Hypertensive Emergency

    CASE REPORT Aortic Thrombus Causing a Hypertensive Emergency Kraftin E. Schreyer, MD*† *Temple University Hospital, Department of Emergency Medicine, Philadelphia, Jenna Otter, MD* Pennsylvania Zachary Johnston, BS† †Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania Section Editor: Rick A. McPheeters, DO Submission history: Submitted February 9, 2017; Revision received June 27, 2017; Accepted June 28, 2017 Electronically published November 3, 2017 Full text available through open access at http://escholarship.org/uc/uciem_cpcem DOI: 10.5811/cpcem.2017.6.33876 Thoracic aorta thrombi are a rare condition typically presenting as a source for distal embolization in elderly patients with atherosclerotic risk factors. However, young patients with a variety of presentations resulting from such thrombi have rarely been reported. We describe a case of a young patient with refractory hypertensive emergency caused by a large thoracic aorta thrombus. Investigation was guided by abnormal physical exam findings. [Clin Pract Cases Emerg Med.2017;1(4):387–390.] INTRODUCTION supine positioning. It had progressively worsened over the Thoracic aorta thrombi are exceedingly rare. When they course of one day and was associated with chest pain, do occur, they typically present as a source of distal subjective fever, and cough productive of blood-tinged embolization, clinically resulting in stroke, transient sputum. According to the patient, he had experienced similar ischemic attack, or arterial embolization of an extremity. symptoms when he was diagnosed with PJP pneumonia. Diagnosis of thoracic aorta thrombi is often made in older On initial exam, the patient had a blood pressure (BP) of patients with atherosclerotic risk factors or known 247/128 mmHg, pulse of 135 beats per minute, and an aneurysmal or atherosclerotic disease.1,2 Thrombi have also oxygen saturation of 86% on room air.
  • Venous Angiomas of the Brain A

    Venous Angiomas of the Brain A

    - REVIEW ARTICLE systems," Venous angiomas may be Venous angiomas of quite small, draining a limited region of the brain, or may be very large, the brain a sometimes draining an entire hemi- • sphere. They can be single or multi- ple, and even bilateral.P" The com- review monest sites of occurrence are in the frontal and parietal lobes of the cere- venous anomaly' or DVA, pointing bral hemispheres and in the cerebel- Ian C Duncan out that these abnormalities actual- Ium.':" They can also be found in the ly represented an extreme anatomi- FFRad(D)SA occipital and temporal lobes, basal cal variant of the normal venous ganglia and pons." Unitas Interventional Unit POBox 14031 drainage of the brain. Lytlelton Imaging 0140 Pathology The classical radiographic appear- The theory of the development of ance of these abnormalities accurately venous angiomas is that there is fail- reflects the anatomical picture with Introduction ure of regression of normal embryon- multiple enlarged transmedullary Venous angiomas of the brain, also ic transmedullary venous channels. veins radiating in a wedge or radial termed venous malformations or These persistent transmedullary veins pattern toward the larger collecting developmental venous anomalies run axially through the white matter vein producing the pathognomic (DVA) are commonest of the to drain into a single larger calibre col- 'caput medusae' or 'spoke wheel' intracranial vascular malformations lecting venous trunk. The dilated ter- appearance during the venous phase comprising between 50% and 63% of minal collecting vein then penetrates of a cerebral angiogram (Figs 1,2).14,15 all intracranial vascular malforma- the cortex to drain either superficially A similar appearance is often seen on tions.
  • Evidence-Based Practice Center Systematic Review Protocol

    Evidence-Based Practice Center Systematic Review Protocol

    Evidence-based Practice Center Systematic Review Protocol Project Title: Serum-Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias I. Background and Objectives for the Systematic Review Plasma cell dyscrasias (PCDs) are a spectrum of disorders characterized by the expansion of a population of monoclonal bone-marrow plasma cells that produce monoclonal immunoglobulins.1 At the benign end of the spectrum is monoclonal gammopathy of undetermined significance (MGUS), where the plasma-cell clone usually does not expand. Multiple myeloma (MM) is a plasma cell disorder at the malignant end of the spectrum and is characterized by the neoplastic proliferation of a clone of plasma cells in the bone marrow with resulting end-organ damage, including skeletal destruction (lytic bone lesions), hypercalcemia, anemia, and renal insufficiency. Whereas monoclonal plasma cells generally secrete intact immunoglobulin, in about 20 percent of patients with MM these cells only produce light-chain monoclonal proteins (i.e., light-chain multiple myeloma [LCMM], formerly known as Bence Jones myeloma) and in 3 percent of patients they secrete neither light- nor heavy-chain monoclonal proteins that are detectable by immunofixation (i.e., nonsecretory multiple myeloma [NSMM]).1 In two-thirds of patients with NSMM, a monoclonal protein can be identified by the serum-free light chain (SFLC) assay. Patients with LCMM develop complications related to tissue deposition of light chains, including amyloidosis. Amyloid light-chain (AL) amyloidosis is the most common form of systemic amyloidosis seen in the United States and is characterized by a relatively stable, slow-growing plasma-cell clone that secretes light-chain proteins that form Table 1: Diagnostic criteria and clinical course of selected plasma cell dyscrasias (PCDs)2 Disorder Disease Definition Clinical Course Monoclonal gammopathy of .
  • Prevalence and Incidence of Rare Diseases: Bibliographic Data

    Prevalence and Incidence of Rare Diseases: Bibliographic Data

    Number 1 | January 2019 Prevalence and incidence of rare diseases: Bibliographic data Prevalence, incidence or number of published cases listed by diseases (in alphabetical order) www.orpha.net www.orphadata.org If a range of national data is available, the average is Methodology calculated to estimate the worldwide or European prevalence or incidence. When a range of data sources is available, the most Orphanet carries out a systematic survey of literature in recent data source that meets a certain number of quality order to estimate the prevalence and incidence of rare criteria is favoured (registries, meta-analyses, diseases. This study aims to collect new data regarding population-based studies, large cohorts studies). point prevalence, birth prevalence and incidence, and to update already published data according to new For congenital diseases, the prevalence is estimated, so scientific studies or other available data. that: Prevalence = birth prevalence x (patient life This data is presented in the following reports published expectancy/general population life expectancy). biannually: When only incidence data is documented, the prevalence is estimated when possible, so that : • Prevalence, incidence or number of published cases listed by diseases (in alphabetical order); Prevalence = incidence x disease mean duration. • Diseases listed by decreasing prevalence, incidence When neither prevalence nor incidence data is available, or number of published cases; which is the case for very rare diseases, the number of cases or families documented in the medical literature is Data collection provided. A number of different sources are used : Limitations of the study • Registries (RARECARE, EUROCAT, etc) ; The prevalence and incidence data presented in this report are only estimations and cannot be considered to • National/international health institutes and agencies be absolutely correct.
  • MECHANISMS in ENDOCRINOLOGY: Novel Genetic Causes of Short Stature

    MECHANISMS in ENDOCRINOLOGY: Novel Genetic Causes of Short Stature

    J M Wit and others Genetics of short stature 174:4 R145–R173 Review MECHANISMS IN ENDOCRINOLOGY Novel genetic causes of short stature 1 1 2 2 Jan M Wit , Wilma Oostdijk , Monique Losekoot , Hermine A van Duyvenvoorde , Correspondence Claudia A L Ruivenkamp2 and Sarina G Kant2 should be addressed to J M Wit Departments of 1Paediatrics and 2Clinical Genetics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, Email The Netherlands [email protected] Abstract The fast technological development, particularly single nucleotide polymorphism array, array-comparative genomic hybridization, and whole exome sequencing, has led to the discovery of many novel genetic causes of growth failure. In this review we discuss a selection of these, according to a diagnostic classification centred on the epiphyseal growth plate. We successively discuss disorders in hormone signalling, paracrine factors, matrix molecules, intracellular pathways, and fundamental cellular processes, followed by chromosomal aberrations including copy number variants (CNVs) and imprinting disorders associated with short stature. Many novel causes of GH deficiency (GHD) as part of combined pituitary hormone deficiency have been uncovered. The most frequent genetic causes of isolated GHD are GH1 and GHRHR defects, but several novel causes have recently been found, such as GHSR, RNPC3, and IFT172 mutations. Besides well-defined causes of GH insensitivity (GHR, STAT5B, IGFALS, IGF1 defects), disorders of NFkB signalling, STAT3 and IGF2 have recently been discovered. Heterozygous IGF1R defects are a relatively frequent cause of prenatal and postnatal growth retardation. TRHA mutations cause a syndromic form of short stature with elevated T3/T4 ratio. Disorders of signalling of various paracrine factors (FGFs, BMPs, WNTs, PTHrP/IHH, and CNP/NPR2) or genetic defects affecting cartilage extracellular matrix usually cause disproportionate short stature.
  • Advanced Imaging

    Advanced Imaging

    CLINICAL APPROPRIATENESS GUIDELINES ADVANCED IMAGING Appropriate Use Criteria: Imaging of the Brain ARCHIVED SEPTEMBER 28, 2019 These documents have been archived because they have outdated information. They are for historical information only and should not be consulted for clinical use. Current versions of guidelines are available on the AIM Specialty Health website at http://www.aimspecialtyhealth.com/ EFFECTIVE MARCH 9, 2019 Proprietary Approval and implementation dates for specific health plans may vary. Please consult the applicable health plan for more details. AIM Specialty Health disclaims any responsibility for the completeness or accuracy of the information contained herein. 8600 West Bryn Mawr Avenue Appropriate.Safe.Affordable South Tower – Suite 800 Chicago, IL 60631 © 2017 ©©©© 2019 AIM Specialty Health www.aimspecialtyhealth.com 2057-0319 Imaging of the Brain Table of Contents Description and Application of the Guidelines .......................................................................................................... 4 General Clinical Guideline ........................................................................................................................................... 5 Clinical Appropriateness Framework .................................................................................................................... 5 Simultaneous Ordering of Multiple Diagnostic or Therapeutic Interventions .................................................... 5 Repeat Diagnostic Intervention .............................................................................................................................
  • A Novel De Novo 20Q13.32&Ndash;Q13.33

    A Novel De Novo 20Q13.32&Ndash;Q13.33

    Journal of Human Genetics (2015) 60, 313–317 & 2015 The Japan Society of Human Genetics All rights reserved 1434-5161/15 www.nature.com/jhg ORIGINAL ARTICLE Anovelde novo 20q13.32–q13.33 deletion in a 2-year-old child with poor growth, feeding difficulties and low bone mass Meena Balasubramanian1, Edward Atack2, Kath Smith2 and Michael James Parker1 Interstitial deletions of the long arm of chromosome 20 are rarely reported in the literature. We report a 2-year-old child with a 2.6 Mb deletion of 20q13.32–q13.33, detected by microarray-based comparative genomic hybridization, who presented with poor growth, feeding difficulties, abnormal subcutaneous fat distribution with the lack of adipose tissue on clinical examination, facial dysmorphism and low bone mass. This report adds to rare publications describing constitutional aberrations of chromosome 20q, and adds further evidence to the fact that deletion of the GNAS complex may not always be associated with an Albright’s hereditary osteodystrophy phenotype as described previously. Journal of Human Genetics (2015) 60, 313–317; doi:10.1038/jhg.2015.22; published online 12 March 2015 INTRODUCTION resuscitation immediately after birth and Apgar scores were 9 and 9 at 1 and Reports of isolated subtelomeric deletions of the long arm of 10 min, respectively, of age. Birth parameters were: weight ~ 1.56 kg (0.4th–2nd chromosome 20 are rare, but a few cases have been reported in the centile), length ~ 40 cm (o0.4th centile) and head circumference ~ 28.2 cm o fi literature over the past 30 years.1–13 Traylor et al.12 provided an ( 0.4th centile).
  • Hypertensive Emergency

    Hypertensive Emergency

    Presentation of hypertensive emergency Definitions surrounding hypertensive emergency Hypertension: elevated blood pressure (BP), usually defined as BP >140/90; pathological both in isolation and in association with other cardiovascular risk factors Severe hypertension: systolic BP (SBP) >200 mmHg and/or diastolic BP (DBP) >120 mmHg Hypertensive urgency: severe hypertension with no evidence of acute end organ damage Hypertensive emergency: severe hypertension with evidence of acute end organ damage Malignant/accelerated hypertension: a hypertensive emergency involving retinal vascular damage Causes of hypertensive emergency Usually inadequate treatment and/or poor compliance in known hypertension, the causes of which include: Essential hypertension o Age o Family history o Salt o Alcohol o Caffeine o Smoking o Obesity Secondary hypertension o Renal . Renal artery stenosis . Glomerulonephritis . Chonic pyelonephritis . Polycystic kidney disease o Endocrine . Cushing’s syndrome . Conn’s syndrome . Acromegaly . Hyperthyroidism . Phaeochromocytoma o Arterial . Coarctation of the aorta o Drugs . Alcohol . Cocaine . Amphetamines o Pregnancy . Pre-eclamplsia Pathophysiology of hypertensive emergency Abrupt rise in systemic vascular resistance Failure of normal autoregulatory mechanisms Fibrinoid necrosis of arterioles Damage to red blood cells from fibrin deposits causing microangiopathic haemolytic anaemia Microscopic haemorrhage Macroscopic haemorrhage Clinical features of hypertensive emergency Hypertensive encephalopathy o